Oral presentation: November 20, 2026 at 15:00 CET REHOVOT, Israel , Oct. 29, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced the acceptance of an abstract on IM1240, the lead tri-specific antibody from its CAPTN-3 platform, for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics , being held in Barcelona, Spain , on November 18-20, 2026 . Data evaluating IM1240 in treatment-resistant human tumor models, including its multi-arm mechanism of action and the contribution of NKG2A engagement, as well as pharmacokinetic and safety evaluation of CAPTN-3’s conditional CD3 masking approach, will be presented in a plenary session by Amir Horowitz , Ph.D., Associate Professor of Immunology and Immunotherapy, and Oncological Sciences, and a member of the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute , Icahn School of Medicine at Mount Sinai . “We are pleased that our IM1240 abstract has been selected for a plenary session oral presentation at the EORTC-NCI-AACR Symposium,” said Isaac Israel , Interim Chief Executive Officer of Purple Biotech . “We are excited with the progress made in our latest work on the CAPTN-3 platform and its lead candidate IM1240 and we look forward to completing our IND-enabling work and, subject to regulatory clearance, initiating our planned first-in-human clinical study for IM1240 in 2027.” Presentation: Title: Conditionally activated NKG2A-engaging tri-specific antibody remodels IO-resistant human tumor microenvironments with improved tumor killing and pharmacologic safety Session Title: Plenary Session 7: Proffered Papers Abstract Number: ENA26-0137 Presenter: Amir Horowitz , Ph.D., Icahn School of Medicine at Mount Sinai Date and Time: Friday, November 20, 2026 , at 15:00 CET The presentation is planned to be available on the Purple Biotech website following the presentation at the symposium. About Purple Biotech Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity. The Company is focused on advancing CAPTN-3 - a platform of masked tri-specific antibodies that simultaneously target tumors while engaging both T cells and NK cells. Capping technology confines immune activation to the tumor microenvironment, significantly expanding the therapeutic window compared to conventional T-cell engagers. The platform's lead candidate, IM1240, is advancing toward the clinic, and its second candidate, IM1305, is in preclinical development. The Company is headquartered in Rehovot, Israel. For additional information about the Company, please visit: https://purple-biotech.com. Forward-Looking Statements and Safe Harbor Statement Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for CAPTN-3; the process by which such early stage therapeutic candidates could potentially lead to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, prog